Anaptys Acquires Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio Targeting Autoimmune Diseases
Shots:
- As per the agreement, Anaptys will make a one-time up front cash payment of $7M to Centessa, which includes $3M for manufactured & GMP supply of ANB101, with potential milestone payments & royalties on global net sales
- AnaptysBio secures an exclusive global license for ANB101 & the rights to ANB102, an extended half-life BDCA2 modulator allowing infrequent dosing. ANB101 has completed the necessary studies and manufacturing scale-up IND approval. Additionally, it will take charge of all future clinical development.
- Anaptys plans to file an IND for CBS004 (to be renamed ANB101) in H2’24, with the aim of advancing immune cell modulation for improved clinical outcomes in autoimmune diseases
Ref: Globe Newswire | Image: Centessa
Related News:- Centessa Reports the First Patient Dosing in the P-III (ACTION) Study of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
